Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-77
Last updated

Report documents

  1. Extract of dossier assessment

    Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 775 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-77_V1.1_en
    Download file : Extract of dossier assessment (PDF document, 775 kB, EN, not accessible)

  2. Dossier assessment

    Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-77_V1.1
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Dossier assessment

Indication:

First-line treatment of adult patients with advanced non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations

Result of dossier assessment:

Hint of lesser benefit

Additional information

Federal Joint Committee (G-BA)

2025-06-02 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A24-77
Commission
Commission awarded on 30.07.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2024-11-04.

DOI

https://doi.org/10.60584/A24-77_V1.1_en

Connected Projects

  1. Dossier assessment

    Osimertinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-72
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-86
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-45
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-20
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Osimertinib - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-14
    Last updated

    Status: Commission completed

  6. Addendum

    Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Addendum to Project A24-77

    Project no.
    A24-119
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-03
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page